TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02066727
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline is administrated as an adjuvant of lidocaine.
Study: NCT04553692
Drug: Aplitabart (IGM-8444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DR5 Agonist Investigational Drug
Study: NCT04553692
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy Regimen
Study: NCT03610321
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.
Study: NCT03363893
Drug: CT7001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
Study: NCT03158610
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral fluorouracil
Study: NCT00651144
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
Study: NCT05471427
Drug: Taxane chemotherapy
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients underwent taxane chemotherapy according to clinical practice for metastatic prostate cancer
Study: NCT04233437
Drug: MLC1501
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLC1501 capsules (4 capcules (2000 mg) twice a day)
Study: NCT04233437
Drug: CYP Cocktail
Normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg
Study: NCT04233437
Drug: Transporter Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg
Study: NCT00529178
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003896
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00100152
Drug: MK0752, (Notch Inhibitor)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04030234
Drug: Intensive BP treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
Study: NCT04030234
Drug: Standard BP treatment group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
Study: NCT00944632
Drug: Placebo (vehicle ointment)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily topical non-occlusive application for up to 4 weeks
Study: NCT02888275
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01421992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet placebo per day during 3 weeks
Study: NCT03472521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match gabapentin
Study: NCT00343629
Drug: sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03448172
Drug: [14C]PF-05221304
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral dose of \[14C\]PF-05221304 (50 mg/100 µCi liquid formulation)
Study: NCT02076815
Drug: Thromboreductin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
Study: NCT04229771
Drug: Proparacaine Hydrochloride ophthalmic solution, USP 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop instilled in one eye, randomly chosen, as topical anesthetic
Study: NCT01476800
Drug: YM178 OCAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00625183
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00042653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally
Study: NCT00082095
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
Study: NCT00198809
Drug: Biolean + Diet education
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00198809
Drug: Biolean Free + Diet education
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00198809
Drug: Placebo + Diet education
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01990768
Drug: 2 grams TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
Study: NCT04539548
Drug: Dextenza Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4mg insert for intracanalicular use
Study: NCT03116009
Drug: Screening for diabetes with 1-hour GCT and HbA1
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
Study: NCT01526278
Drug: Maxmarvil®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
Study: NCT01153009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching capsules
Study: NCT00401193
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01048944
Drug: Placebo Patch and Placebo Pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
Study: NCT01709864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
Study: NCT03250338
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally
Study: NCT02660684
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection
Study: NCT01613079
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
Study: NCT00910117
Drug: PF regimen (cisplatin and 5-FU)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
Study: NCT02802696
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
Study: NCT03372382
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NSAID
Study: NCT03372382
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: analgesic
Study: NCT02153125
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04287049
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 250 mg PO daily
Study: NCT00481364
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tb/day
Study: NCT00020202
Drug: FR901228
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04557436
Drug: PBLTT52CAR19
Approvals — FDA: no, EMA: no, PMDA: no
Description: gene therapy
Study: NCT00004464
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03251482
Drug: JNJ-64179375 A mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64179375 Dose A mg/kg IV as a single dose on Day 1.
Study: NCT03251482
Drug: JNJ-64179375 C mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64179375 Dose C mg/kg IV as a single dose on Day 1.
Study: NCT03251482
Drug: JNJ-64179375 D mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64179375 Dose D mg/kg IV as a single dose on Day 1.
Study: NCT03251482
Drug: Placebo JNJ-64179375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.
Study: NCT04661852
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV, over 30 minutes (schedule based upon dose level)
Study: NCT00561587
Drug: Seroquel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
Study: NCT01360853
Drug: ON 01910.Na
Approvals — FDA: no, EMA: no, PMDA: no
Description: ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
Study: NCT02849886
Drug: Dimerizer drug AP1903
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:~* Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;~* Grade ≥3 toxicity attributable to GMC.
Study: NCT01220726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection
Study: NCT06178718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebo will be administered once in each group.
Study: NCT02878096
Drug: [14C]-SK-1404
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of \[14C\]-SK-1404.
Study: NCT02688803
Drug: Dose dense AC-P
Approvals — FDA: no, EMA: no, PMDA: no
Description: (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
Study: NCT02688803
Drug: Dose dense AC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
Study: NCT02688803
Drug: FEC-D
Normalized name: Fluorouracil, Epirubicin, and Cyclophosphamide followed by Docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
Study: NCT01502956
Drug: Botox® injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
Study: NCT04392219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.
Study: NCT00449917
Drug: vitamins
Normalized name: Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04449276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study: NCT01709968
Drug: MAGNOX 520®
Approvals — FDA: no, EMA: no, PMDA: no
Description: un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
Study: NCT01709968
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similarly looking placebo. Oral administration once daily for 4 weeks
Study: NCT00088972
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00857467
Drug: NRL001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
Study: NCT00857467
Drug: NRL001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
Study: NCT00214214
Drug: Campath 1H® (Alemtuzumab)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02210325
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01915550
Drug: Humulin Insulin Mixtard
Normalized name: insulin isophane / insulin, regular, human Pen Injector [Humulin]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00619372
Drug: OKT3, GC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
Study: NCT00619372
Drug: OKT3, GC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
Study: NCT03594955
Drug: SAR440234
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:lyophilisate to be resuspended in solution Route of administration: intravenous
Study: NCT00495690
Drug: Oral zinc gluconate (5 mg elemental)
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
Study: NCT03446209
Drug: 0.9% physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get rescue medication after week 16 to week 28.
Study: NCT01680952
Drug: B) CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Extended Release Tacrolimus (Advagraf®)~   : Same as above.~2. Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid
Study: NCT01584505
Drug: CHF1535 + CHF5992 dose 1 BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF1535 + CHF5992 dose 1 BID for 14 days
Study: NCT01584505
Drug: CHF1535 + CHF5992 dose2 BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF1535 + CHF5992 dose 2 BID for 14 days
Study: NCT01584505
Drug: CHF1535 daily dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF1535 daily dose for 14 days
Study: NCT00504543
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, twice daily
Study: NCT00815503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT01247675
Drug: ACP-001 (TransCon hGH)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: s.c., weekly injection
Study: NCT00621725
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: NCT03718234
Drug: Subcutaneous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be monitored and receive an interval bolus SQHC dosing regimen that more closely mimics cortisol, 17OHP and D4A circadian and ultradian rhythms than conventional oral HC dosing.
Study: NCT03718234
Drug: Standard glucocorticoid therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will continue on standard oral hydrocortisone therapy
Study: NCT01090050
Drug: Naproxen Sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
Study: NCT02933528
Drug: DSXS Topical product
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for 28 days
Study: NCT03539484
Drug: RO7172508
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7172508 was administered at a dose and as per the schedule specified in the respective arms.
Study: NCT02983461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet, 3 times a day for 10 weeks
Study: NCT02256735
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritobegron Cl (KUC 7483 CL) tablets low dose
Study: NCT02256735
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02256735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02496039
Drug: NUEDEXTA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUEDEXTA® only
Study: NCT02699827
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive epidural 5 ml saline 0.9%
Study: NCT02103699
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
Study: NCT03374488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally twice daily.
Study: NCT05386290
Drug: conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment includes glucocoticoid, immunosupressive drugs and/or mesalazine. Immunosupressive drugs include azathioprine (AZA), methotrexate (MTX) and thalidomide (THA).
Study: NCT01005901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation capsules were provided for use via a SDDPI
Study: NCT04430088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 0 mg of VVZ-149
Study: NCT03201965
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.
Study: NCT00338221
Drug: glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02608242
Drug: YH22189
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02608242
Drug: Twynsta 80/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00243971
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00272844
Drug: crystalline cholesterol oil-based suspension
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
Study: NCT00893139
Drug: AL-38583 ophthalmic solution 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00893139
Drug: AL-38583 ophthalmic solution 0.10%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02088398
Drug: ACY-1215
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01690195
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT01263717
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
Study: NCT03696199
Drug: Long-Acting Local Anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cocktail consists of:~* 0.5% Ropivicaine, 24.6 mL~* Clonidine 100 mcg/mL, 0.4mL~* Epinephrine 1mg/mL, 0.5mL~* Saline to total volume of 50 mL (24.5mL of saline)~The total amount of solution prepared is 50mL, but typically 30mL is used based on the size of the incision. The total volume administered will be recorded.
Study: NCT03696199
Drug: Regional Anesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivicaine - 30mL each sciatic and femoral/saphenous nerve, ultrasound guided
Study: NCT00933985
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01397149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form, frequency and duration exactly as experimental arm.